Regional therapy in metastatic melanoma: An update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 10, 2014, Pages 1355-1364

  Rashid, Omar M ^a   Sloot, Sarah ^a   Zager, Jonathan S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

In transit melanoma; Isolated limb infusion; Melanoma liver metastasis; Melphalan; Percutaneous hepatic perfusion; Uveal melanoma

Indexed keywords

BEVACIZUMAB; DOXORUBICIN; FLUOROURACIL; IPILIMUMAB; MELPHALAN; SORAFENIB; ANTINEOPLASTIC AGENT;

ANEMIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CATHETER COMPLICATION; DISEASE FREE SURVIVAL; DRUG DELIVERY SYSTEM; GASTRITIS; HUMAN; HYPERTHERMIC THERAPY; IN-TRANSIT METASTASIS; INFUSION; INOPERABLE CANCER; INTRAARTERIAL DRUG ADMINISTRATION; ISOLATED LIMB INFUSION; LIMB DISEASE; LIVER METASTASIS; LIVER PERFUSION; METASTATIC MELANOMA; MINIMALLY INVASIVE PROCEDURE; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; PERCUTANEOUS HEPATIC PERFUSION; PHASE 1 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; REGIONAL PERFUSION; REVIEW; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE; LIVER NEOPLASMS; MELANOMA; METASTASIS; PATHOLOGY; PROCEDURES; SECONDARY; SKIN NEOPLASMS;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MELANOMA; NEOPLASM METASTASIS; SKIN NEOPLASMS;

EID: 84907177847     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.951330     Document Type: Review

References (54)

1. Alexander HR Jr, Butler CC. Development of isolated hepatic perfusion via the operative and percutaneous techniques for patients with isolated and unresectable liver metastases. Cancer J 2010;16:132-41
2. Gimbel MI, Delman KA, Zager JS. Therapy for unresectable recurrent and in-transit extremity melanoma. Cancer Contr 2008;15:225-32
3. Padsis J, Turley R, Tyler D. Pharmacotherapy of regional melanoma therapy. Expert Opin Pharmacother 2010;11:79-93
4. Lawrence W Jr. Regional cancer chemotherapy: An evaluation. Prog Clin Cancer 1965;10:341-93
5. Lawrence W Jr, Clarkson B, Kim M, et al. Regional perfusion of pelvis and abdomen by an indirect technique. Acta Unio Int Contra Cancrum 1964;20:469-73
6. Lawrence W Jr, Kuehn P, Masle ET, Miller DG. An abdominal tourniquet for regional chemotherapy. J Surg Res 1961;1:142-51
7. Lawrence W Jr, Kuehn P, Mori S, et al. Regional perfusion of the pelvis: Consideration of the leakage problem. Surgery 1961;50:248-59
8. Han D, Beasley GM, Tyler DS, Zager JS. Minimally invasive intraarterial regional therapy for metastatic melanoma: Isolated limb infusion and percutaneous hepatic perfusion. Expert Opin Drug Metab Toxicol 2011;7:1383-94
9. Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003;44:4651-9
10. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206
11. Zogakis TG, Bartlett DL, Libutti SK, et al. Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma. Ann Surg Oncol 2001;8:771-8
12. Beasley GM, Petersen RP, Yoo J, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: A well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 2008;15:2195-205
13. Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 2008;15:3003-13
14. Raymond AK, Beasley GM, Broadwater G, et al. Current trends in regional therapy for melanoma: Lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg 2011;213:306-16
15. Chai CY, Deneve JL, Beasley GM, et al. A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities. Ann Surg Oncol 2012;19:1637-43
16. Vohra NA, Turaga KK, Gonzalez RJ, et al. The use of isolated limb infusion in limb threatening extremity sarcomas. Int J Hyperthermia 2013;29:1-7
17. Wong J, Chen YA, Fisher KJ, Zager JS. Isolated limb infusion in a series of over 100 infusions: A single-center experience. Ann Surg Oncol 2013;20:1121-7
18. Bonenkamp JJ, Thompson JF, de Wilt JH, et al. Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable locoregional melanoma recurrence. Eur J Surg Oncol 2004;30:1107-12
19. Ueno T, Ko SH, Grubbs E, et al. Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. Am J Surg 2004;188:532-7
20. Quirt I, Verma S, Petrella T, et al. Temozolomide for the treatment of metastatic melanoma: A systematic review. Oncologist 2007;12:1114-23
21. Beasley GS, Speicher PJ, Jiang B, et al. A multi-center phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion. Society of Surgical Oncology Cancer Symposium; Phoenix, AZ; 2014; Duke University. A Phase I trial evaluating the efficacy and safety of a novel agent( temozolomide) in an ILI circuit
22. Turaga KK, Beasley GM, Kane JM III, et al. Limb preservation with isolated limb infusion for locally advanced nonmelanoma cutaneous and soft-tissue malignant neoplasms. Arch Surg 2011;146:870-5
23. Grubbs EG, Rich TA, Li G, et al. Recent advances in thyroid cancer. In brief. Curr Probl Surg 2008;45:149-51
24. Wu PC, McCart A, Hewitt SM, et al. Isolated organ perfusion does not result in systemic microembolization of tumor cells. Ann Surg Oncol 1999;6:658-63
25. Santillan AA, Delman KA, Beasley GM, et al. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: A multiinstitutional analysis. Ann Surg Oncol 2009;16:2570-8
26. Thompson JF. Local and regional therapies for melanoma: Many arrows in the quiver. J Surg Oncol 2014;109:295
27. Roberts MS, Wu ZY, Siebert GA, et al. Saturable dose-response relationships for melphalan in melanoma treatment by isolated limb infusion in the nude rat. Melanoma Res 2001;11:611-18
28. Cheng TY, Grubbs E, Abdul-Wahab O, et al. Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. Am J Surg 2003;186:460-7
29. McMahon N, Cheng TY, Beasley GM, et al. Optimizing melphalan pharmacokinetics in regional melanoma therapy: Does correcting for ideal body weight alter regional response or toxicity? Ann Surg Oncol 2009;16:953-61
30. Harada N, Nagasaki A, Hata H, et al. Down-regulation of CD98 in melphalanresistant myeloma cells with reduced drug uptake. Acta Haematol 2000;103:144-51
31. Clark J, Grabs AJ, Parsons PG, et al. Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma. Melanoma Res 1994;4:365-70
32. Abdel-Wahab OI, Grubbs E, Viglianti BL, et al. The role of hyperthermia in regional alkylating agent chemotherapy. Clin Cancer Res 2004;10:5919-29
33. Muilenburg DJ, Thompson ZJ, Lee J, Zager JS. Disease burden predicts response to melphalan-based isolated limb infusion in melanoma. H. Lee Moffitt Cancer Center and Research Institute, Presented at the Society of Surgical Oncology Annual Meeting, Phoenix, AZ, 2014
34. Augustine CK, Yoshimoto Y, Gupta M, et al. Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. Cancer Res 2008;68:3777-84
35. Toshimitsu H, Yoshimoto Y, Augustine CK, et al. Inhibition of poly( ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma. Ann Surg Oncol 2010;17:2247-54
36. Dickson PV, Hamner JB, Sims TL, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007;13:3942-50
37. Turley RS, Fontanella AN, Padussis JC, et al. Bevacizumab-induced alterations in vascular permeability and drug delivery: A novel approach to augment regional chemotherapy for in-transit melanoma. Clin Cancer Res 2012;18:3328-39
38. Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007;12:426-37
39. Beasley GM, Sharma K, Wong J, et al. A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion. Cancer 2012;118:6136-43
40. Jilaveanu L, Zito C, Lee SJ, et al. Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clin Cancer Res 2009;15:1076-85
41. Kim MW, Blum C, Alosi AB, et al. Combined with Isolated Limb Perfusion( ILP) for extremity melanoma. Roswell Park Cancer Institute; 2014
42. Sato T. Locoregional management of hepatic metastasis from primary uveal melanoma. Semin Oncol 2010;37:127-38
43. Agarwala SS, Eggermont AM, O'Day S, Zager JS. Metastatic melanoma to the liver: A contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. Cancer 2014;120:781-9
44. Beheshti MV, Denny DF Jr, Glickman MG, et al. Percutaneous isolated liver perfusion for treatment of hepatic malignancy: Preliminary report. J Vasc Interv Radiol 1992;3:453-8
45. Feldman ED, Pingpank JF, Alexander HR Jr. Regional treatment options for patients with uveal melanoma metastatic to the liver. Ann Surg Oncol 2004;11:290-7
46. Ausman RK. Development of a technic for isolated perfusion of the liver. N Y State J Med 1961;61:3993-7
47. Pingpank JF, Hughes MS, Faries MB, et al. A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic uveal or cutaneous melanoma. J Clin Oncol 2010;28(18S Suppl):abstract LBA8512
48. Pingpank JF, Libutti SK, Chang R, et al. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 2005;23:3465-74
49. Yamamoto M, Zager JS. Isolated hepatic perfusion for metastatic melanoma. J Surg Oncol 2014;109:383-8
50. Forster MR, Rashid OM, Perez MC, et al. Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: A single institution experience. J Surg Oncol 2014;109:434-9
51. Fitzpatrick M, Richard Alexander H, Deshpande SP, et al. Use of partial venovenous cardiopulmonary bypass in percutaneous hepatic perfusion for patients with diffuse, isolated liver metastases: A case series. J Cardiothorac Vasc Anesth 2014;28(3):647-51
52. Ravikumar TS, Pizzorno G, Bodden W, et al. Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors. J Clin Oncol 1994;12:2723-36
53. Alexander HR. Percutaneous hepatic perfusion (PHP or ChemoSat) with melphalan versus best alternative care (BAC) in patients (pts) with hepatic metastases from melanoma: A post hoc analysis of PHP-randomized versus BAC-to-PHP crossover versus BAC-only pts. J Clin Oncol 2012;30(Suppl):abstract 8570
54. van Ijken MG, de Bruijn EA, de Boeck G, et al. Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: A pharmacokinetic study in pigs. Ann Surg 1998;228:763-70